Search Results for “EC” – Page 345 – media

Roche Cuts Pipeline as COVID, Currency Headwinds Impact Q3 Results

Pictured: Roche tower in Switzerland/iStock, olli0815 Roche is eliminating four clinical programs amid drooping sales brought about by a sharp decline in demand for COVID-19 products and a strong Swiss franc, the pharma group announced Thursday morning in its third-quarter earnings results. According to a development pipeline document released alongside the quarterly report, Roche will end a Phase I solid tumor trial for its investigational CEA/CD3 bispecific antibody cibisatamab. The company will also stop Phase II trials of its antipsychotic drug candidate ralmitaront in schizophrenia and the developmental cannabinoid receptor agonist vicasinabin in diabetic retinopathy. Roche discontinued the mid-stage study of ralmitaront after it failed a Phase II trial in May 2023, unable to elicit significant improvements on negative symptoms in a preliminary analysis. The vicasinabin and cibisatamab programs were likewise scrapped following underwhelming reviews of their efficacy in their respective studies. However, in a media call Thursday morning, a Roche spokesperson said that these two ...
- Source: By Tristan Manalac
- 137
- October 31, 2023
Supply disruptions are delaying surgeries and compromising patient care, survey finds

Dive Brief Shortages of medical devices and therapies are compromising patient care by delaying treatment and driving unsafe practices, according to a survey of healthcare professionals conducted by the patient safety nonprofit ECRI and the Institute for Safe Medication Practices. The survey found that supply shortages have caused surgical cases to be rescheduled, postponed or canceled, and that a lack of endotracheal tubes and pulmonary artery catheters is on the cusp of impacting the ability to provide adequate clinical care. ECRI and the Institute for Safe Medication Practices used the findings to call for “long-term, nationally coordinated solutions” to stop persistent shortages. Dive Insight The Food and Drug Administration currently lists 11 medical devices that are in short supply. More than 120 drugs face shortages, according to another FDA list. The tendency for some products to become hard to source, for reasons such as manufacturing problems and rising demand, predates ...
- Source: https://www.medtechdive.com/news/supply-disruptions-delaying-surgeries-ecri/697140/
- 211
- October 31, 2023
Pupil size may predict response to TMS treatment for depression

New findings from researchers at UCLA Health suggest that measuring changes in how pupils react to light could help predict recovery from depression and personalize transcranial magnetic stimulation (TMS) treatment of major depressive disorder. TMS is a safe, non-invasive therapy that uses magnetic fields to stimulate parts of the brain involved in mood regulation. While TMS is proven effective, not all patients respond equally well to the therapy. The ability to predict who will benefit most could allow doctors to better customize and target treatments. In two recent studies, UCLA scientists found that the pupil’s response to light before treatment correlated with improvements in depression symptoms over the course of therapy. Pupil size reflects activation of the autonomic nervous system, which controls involuntary functions and is negatively impacted in people with depression. The first study, appearing in the Journal of Affective Disorders, reports on outcomes for 51 patients who underwent ...
- Source: https://www.news-medical.net/news/20231020/Pupil-size-may-predict-response-to-TMS-treatment-for-depression.aspx
- 115
- October 31, 2023
Drugdu.com Unveils Digital Medical Trade Solutions at CPhI Barcelona

The prestigious CPhI Worldwide Europe 2023 once again provided a dynamic platform for global suppliers, innovators, and pharmaceutical professionals to showcase their offerings and engage in valuable exchanges. The event, staged at the Barcelona Exhibition Center from October 24th to 26th, saw a remarkable gathering of 2,500 exhibitors and 45,000 attendees from around the globe. Amidst this impressive assembly, Drugdu.com made a notable appearance, unveiling its avant-garde digital solutions. Marking its eighth consecutive participation at the CPhI exhibition, Drugdu.com stood out with a captivating booth design that emanated vibrancy and creativity, attracting a multitude of industry experts. As a B2B platform heralding the integration of digitization in medical trade, Drugdu.com utilized this opportunity to share groundbreaking digital solutions, showcasing its profound expertise and market insight. The innovative approach was met with high acclaim and recognition from attendees, asserting a pivotal role in enhancing industry efficiency and spearheading the digital transformation ...
- Source: drugdu
- 237
- October 27, 2023
Lack of Autonomy Is a Major Reason Clinicians Are Exiting the Field

Patient safety and lack of autonomy are two of the biggest reasons why so many clinicians are leaving the medical field, according to a new report published by EY. Amid the clinical burnout crisis, healthcare workers have spoken candidly about their moral injury, which refers to the feeling of knowing that they aren’t able to provide patients with the quality of care they need and deserve due to workforce and resource constraints. Clinicians’ concerns about patient safety are a major factor driving their exits from the field, and this is something that has been covered extensively by the media and is well-known within the healthcare sector, pointed out Aloha McBride, EY’s global health leader, in an interview. Clinicians’ grievances about their lack of control when it comes to making decisions about their patients’ care plans is a less-discussed subject, though. For its report, EY conducted more than 100 interviews with frontline clinicians and health system executives between ...
- Source: drugdu
- 133
- October 27, 2023
Daiichi Sankyo, Merck Set to Collaborate on Three DXd Antibody-Drug Conjugates

Image Credit: Adobe Stock Images/huenstructurebio.com Daiichi Sankyo and Merck announced that they have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd) and raludotatug deruxtecan (R-DXd). Reportedly, the companies will jointly develop and potentially commercialize the candidates globally, except for Japan where Daiichi Sankyo will maintain exclusive rights. “The promising results from clinical trials of patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan continue to demonstrate the broad applicability of Daiichi Sankyo’s DXd ADC technology across multiple targets, with each of these medicines having the potential to change clinical practice as has been already seen with Enherti,” said Sunao Manabe, representative director, executive chairperson, CEO, Daiichi Sankyo Company, Limited. “As Daiichi Sankyo continues its transformation into a global oncology leader by increasingly building our infrastructure and talent, we recognize that a collaboration with Merck, a company ...
- Source: drugdu
- 129
- October 27, 2023
Intuitive leaders weigh in on GLP-1 drugs and surgical robotics procedures

Intuitive Surgical Chief Medical Officer Dr. Myriam Curet [Photo courtesy of Intuitive Surgical] Intuitive Surgical (Nasdaq: ISRG)+ executives say they see benefits to their business from GLP-1 weight loss drugs, even if investors aren’t quite so sure.Intuitive’s stock slid in after-hours trading today after the company posted Q3 results that exceeded analysts’ expectations on profits but fell short on sales. Even if they had beat The Street on both counts, it’s not clear investors would have reacted any differently — just look at what happened to Intuitive’s stock price under that exact scenario after Q2.In Q2, the company said bariatric procedure growth slowed due to patient interest in weight loss drugs. Related: Analysts expect minor GLP-1 impact on insulin pumps, but a boost for CGMs“Bariatric procedures represent between four and 5% of total global procedures,” CFO Jamie Samath said on the Q3 call. “Based on third-party data, we believe we continue to gain market share in the ...
- Source: drugdu
- 122
- October 27, 2023
Indivior Agrees to Pay $385M Amid Monopoly Lawsuit

Indivior, an addiction treatment company, announced that it has reached an agreement with wholesalers to resolve their claims of suppressing competition for its opioid addiction drug, Suboxone. As a result of the agreement, the upcoming trial, scheduled for Oct 30, has been cancelled. Reportedly, Indivior will pay $385 million and will take a charge of $228 million in the third quarter, which will be excluded from adjusted earnings. “We are pleased to achieve this settlement to conclude this legacy multi-district antitrust matter,” said Mark Crossley, CEO, Indivior. “The resolution of this litigation, which was filed over a decade ago, provides greater certainty for all Indivior stakeholders and allows us to continue focusing on our important work for patients suffering from opioid use disorder and mental health illnesses around the world.”
- Source: drugdu
- 119
- October 27, 2023
Disruptors of This Industry Are Already in It

A Formula 1 racing car is no joke. It’s purpose built, at great cost, at state of the art facilities with wind tunnels to improve aerodynamic performance and speed. The goal is simple: to win on tracks like the iconic Silverstone. It would be dangerously pointless to take an F1 car to the desert, smashing it through sand and into rocks, and expect it to perform the same. But today in healthcare, a host of new entrants and stakeholders is doing exactly that.Companies built for other businesses are attempting to offroad their skills into a brand new field. These fairweather healthcare players are unprepared for the terrain. Meanwhile, the true disruptors of this industry are already in it. When you hear newbies and big tech brands hyping AI, for example, delivered via ChatGPT, Microsoft, and others, as a way to transform healthcare, listen up. The bluster is a giveaway. Sure, ...
- Source: drugdu
- 107
- October 27, 2023
Intuitive leaders weigh in on GLP-1 drugs and surgical robotics procedures

BY JIM HAMMERAND Intuitive Surgical Chief Medical Officer Dr. Myriam Curet [Photo courtesy of Intuitive Surgical] Intuitive Surgical (Nasdaq: ISRG)+ executives say they see benefits to their business from GLP-1 weight loss drugs, even if investors aren’t quite so sure. Intuitive’s stock slid in after-hours trading today after the company posted Q3 results that exceeded analysts’ expectations on profits but fell short on sales. Even if they had beat The Street on both counts, it’s not clear investors would have reacted any differently — just look at what happened to Intuitive’s stock price under that exact scenario after Q2. Related: Analysts expect minor GLP-1 impact on insulin pumps, but a boost for CGMs So it was no surprise that the very first question for Intuitive leaders from analysts on today’s Q3 earnings call focused on the impact of GLP-1 drugs on bariatric procedures. “I think in the short term, we will see patients who are considering or are ...
- Source: drugdu
- 135
- October 21, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.